Acta oncologica (Stockholm, Sweden) · 2025
Radium-223 use and survival by line of treatment in metastatic castration-resistant prostate cancer: a nationwide population-based register study.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Alverbratt Charlotte, Sandin Fredrik, Kolmbäck Viktor, Garmo Hans, Bratt Ola, Franck Lissbrant Ingela
Аннотация
BACKGROUND: The role and optimal sequencing of radium-223 in the treatment of metastatic castration-resistant prostate cancer (mCRPC) remain debated. In Europe, radium-223 is restricted to third line treatment or later for chemotherapy-eligible men, although studies suggest greater benefit with earlier use. In this nationwide, population-based study, we investigated radium-223 use in Sweden and analyzed the association between line of treatment and overall survival.
METHODS: Men with mCRPC who started radium-223 in 2014-2020 were identified in national registers. The Kaplan-Meier method was used to estimate survival. The association between line of treatment and survival was analyzed with Cox regression and presented as adjusted hazard ratios (aHRs) with 95% confidence intervals (CIs). A subgroup with at least three mCRPC treatment lines was similarly analyzed.
RESULTS: 1,133 men were included. Median overall survival was 13.9 months (95% CI 13.0-14.5). Later line of radium-223 treatment was associated with shorter survival; with first line as reference, aHR for death for second line was 1.34 (95% CI 1.12-1.59) and for third line 1.55 (1.29-1.87). The opposite was observed for 596 men with at least three lines of mCRPC treatment: aHR for second line was 0.80 (0.59-1.08) and for third line 0.78 (0.59-1.03).
INTERPRETATION: Survival after start of radium-223 in Sweden was comparable to pivotal trials, suggesting effective use. Our overall results do not suggest a better effect of radium-223 in first versus later mCRPC treatment lines but rather emphasize the value of a randomized controlled trial to more definitely determine the optimal timing of radium-223 treatment.
METHODS: Men with mCRPC who started radium-223 in 2014-2020 were identified in national registers. The Kaplan-Meier method was used to estimate survival. The association between line of treatment and survival was analyzed with Cox regression and presented as adjusted hazard ratios (aHRs) with 95% confidence intervals (CIs). A subgroup with at least three mCRPC treatment lines was similarly analyzed.
RESULTS: 1,133 men were included. Median overall survival was 13.9 months (95% CI 13.0-14.5). Later line of radium-223 treatment was associated with shorter survival; with first line as reference, aHR for death for second line was 1.34 (95% CI 1.12-1.59) and for third line 1.55 (1.29-1.87). The opposite was observed for 596 men with at least three lines of mCRPC treatment: aHR for second line was 0.80 (0.59-1.08) and for third line 0.78 (0.59-1.03).
INTERPRETATION: Survival after start of radium-223 in Sweden was comparable to pivotal trials, suggesting effective use. Our overall results do not suggest a better effect of radium-223 in first versus later mCRPC treatment lines but rather emphasize the value of a randomized controlled trial to more definitely determine the optimal timing of radium-223 treatment.